iiinova — where your digital self keeps evolving

Reposted by Jiuling Yang

Deniz Gökbuget @denizgoekbuget.bsky.social · 04/02/2025

🚨 New Paper Alert! 🚨 Our latest study on KMT2C/KMT2D (mutated in 20% of cancers) reveals a new function for H3K4me1 in regulating DNA replication timing (RT) and origin activity during cell state transitions. Check it out: www.cell.com/cell-reports.... More info ⬇️

cell.com

KMT2C/KMT2D-dependent H3K4me1 mediates changes in DNA replication timing and origin activity during a cell fate transition

Gökbuget et al. use machine learning to quantify chromatin state changes that predict DNA replication timing changes during cell differentiation. By following up on top predictors through functional v...

22610

Reposted by Jiuling Yang

Blelloch Lab UCSF @rblellochlab.bsky.social · 14/11/2024

Huaigeng is presenting his exciting work on developing cancer vaccines today at the UCSF Prostate Program retreat.

Huaigeng Xu at the podium ready to give his presentation.

264

Reposted by Jiuling Yang

Blelloch Lab UCSF @rblellochlab.bsky.social · 11/11/2024

The Blelloch Lab held a retreat in the Tahoe National Forest this weekend. We decided to join the Bluesky Science Community.

0103

Jiuling Yang @jiulingy.bsky.social · 13/11/2024

I'm excited to share a new publication from my previous lab building on our earlier work on PROTAC degraders targeting MDM2 for cancer therapy. More efficient MDM2 degraders have been developed as we gain deeper insights into their mechanisms. Check it out if interested! pubs.acs.org/doi/full/10....

pubs.acs.org

Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia

MDM2 has been pursued as an attractive therapeutic target for human cancers. Herein, we describe our discovery of MD-265 as a promising PROTAC MDM2 degrader and extensive in vitro and in vivo evaluati...

032